Breaking News, Collaborations & Alliances

Gilead, Dragonfly Enter Onco & Inflammation Strategic Alliance

Gilead to license exclusive rights to the investigational candidate DF7001, a 5T4-Targeting NK cell engager for solid tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences, Inc. and Dragonfly Therapeutics entered a collaboration to advance a number of Dragonfly’s novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other disease areas such as inflammation.    Gilead will receive an exclusive, worldwide...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters